Roche introduces X-tremeGENE 9, X-tremeGENE HP reagents

Roche (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY) announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research. Designed for commonly used and hard-to-transfect cell lines, the X-tremeGENE 9 and X-tremeGENE HP reagents offer high efficiency, reproducibility and cell survival rates, compared to leading transfection reagents, to deliver more viable cells and help accelerate research efforts. Both reagents support a wide variety of cellular and molecular research applications, such as gene expression analysis and protein production.

The two new products build on Roche's 20 years of experience with transfection reagents. The X-tremeGENE 9 reagent offers efficient performance across a wide variety of commonly used cell lines while Roche's X-tremeGENE HP reagent is especially well suited for cell lines that are difficult to transfect or not easily transfected with other reagents.

Both reagents combine low cytotoxicity with high efficiency and reproducibility, providing more viable cells with more physiologically relevant results. They also offer easy-to-implement protocols: Researchers simply dilute the reagent, incubate it with plasmid DNA, and pipette it directly onto cells. The simple process enables researchers to spend less time optimizing the reagent and more time advancing their research.

Both reagents function well in the presence or absence of serum and remain stable after repeated vial openings, helping to save researchers time and effort.